

General information

Speakers

Organizers



UNIVERSITÀ
DEGLI STUDI
DI MILANO



Publication

Accepted abstracts will be published on *Journal of NeuroVirology*

Site of the Symposium

Grand Hotel Bristol

C.so Umberto I, 73 - 28838 Stresa (VB) ITALY

Tel. +39 0323 32601

<http://bristol.zaccherahotels.com/it>

Gala Dinner

"Ristorante Delfino" - Isola Bella

Friday, May 10th

Meeting point: 6.45 PM in the hall of Grand Hotel Bristol

Please, be on time since the gala dinner will be preceded by a sightseeing cruise of 40 minutes. Smart dress not required.

Registration Fee

Participation fee	Early bird registration until February 15 th , 2013	From February 16 th to May 3 rd , 2013	On site registration (only cash)
Standard	250 VAT included	300 VAT included	400 VAT included
Student	100 VAT included	150 VAT included	200 VAT included

Standard registration fee includes: Conference Kit, certificate of attendance, coffee breaks, buffet lunch on Thursday, May 9th.

Student registration fee includes: Conference Kit, certificate of attendance and coffee breaks.

Registration methods

All participants are required to register using the "online form", which can be found on www.bquadro-congressi.it and to pay by wire transfer.

Payment methods

To finalize the registration to the congress, it is mandatory to send a copy of the wire transfer of the registration fee to bolla@bquadro-congressi.it or to fax number +39 0382 27697. ALL WIRE TRANSFER CHARGES ARE ON THE PARTICIPANT. The wire transfer must be headed to:

5th INTERNATIONAL CONFERENCE ON POLYOMAVIRUSES ORGANIZING COMMITTEE

Via S. Giovanni in Borgo, 4 - 27100 Pavia, Italy

IBAN: IT40W 05584 01667 0000 0000 2666

SWIFT CODE: BPMIITMMXXX

In "Cause" box please write: **name, family name and "Registration Fee"**

Cancellation and refunds

Info on website www.bquadro-congressi.it

ECM

The following professional roles will receive Formation Credits upon attending to the congress:

- **MD** (Anatomical Pathology, Hygiene, Epidemiology and Public Health, Infectious Diseases, Microbiology and Virology, Neurology, Oncology);

- **Biologists, Biomedical Technician Laboratories.**

17 ECM credits have been pre-assigned.

Joseph BERGER	University of Kentucky, Lexington (USA)
Renzo BOLDORINI	University of East Piedmont, Novara (Italy)
Chris BUCK	National Cancer Institute, Bethesda (USA)
Michele CARBONE	University of Hawaii Cancer Center, Honolulu (USA)
Manola COMAR	University of Trieste, Trieste (Italy)
Serena DELBUE	University of Milan, Milan (Italy)
Bernhard EHLERS	Robert Koch-Institut, Berlin (Germany)
Mariet FELTKAMP	Leiden University Medical Center, Leiden (The Netherlands)
Pasquale FERRANTE	University of Milan, Milan (Italy)
Jennifer GORDON	Temple University School of Medicine, Philadelphia (USA)
Hans H. HIRSCH	University of Basel, Basel (Switzerland)
Edward M. JOHNSON	Eastern Virginia Medical School, Norfolk (USA)
Kamel KHALILI	Temple University School of Medicine, Philadelphia (USA)
Igor KORALNIK	Beth Israel Deaconess Medical Center, Boston (USA)
Ugo MOENS	University of Tromso, Tromso (Norway)
Patrick S. MOORE	University of Pittsburgh Cancer Institute, Pittsburgh (USA)
Joseph S. PAGANO	University of North Carolina and Chapel Hill, Chapel Hill (USA)
Valeria PIETROPAOLO	University Sapienza, Roma (Italy)
Maurizio PROVENZANO	University Hospital, Zurich (Switzerland)
Parmjeet RANDHAWA	University of Pittsburgh School of Medicine, Pittsburgh (USA)
Mahmut SAFAK	Temple University School of Medicine, Philadelphia (USA)
Walter ROYAL III	University of Maryland Medical Center, Baltimore (USA)
Ilker SARIYER	Temple University School of Medicine, Philadelphia (USA)
Hirofumi SAWA	Hokkaido University, Sapporo (Japan)
Gianluca VAGO	University of Milan, Milan (Italy)
Raphael VISCIDI	The Johns Hopkins Hospital, Baltimore (USA)
David WANG	Washington University, St. Louis (USA)

Pasquale Ferrante, Milan (Italy)
pasquale.ferrante@unimi.it

Kamel Khalili, Philadelphia (USA)
kamel.khalili@temple.edu

Scientific Committee

Renzo Boldorini, Novara (Italy)
renzo.boldorini@med.unipmn.it

Hans H. Hirsch, Basel (Switzerland)
hans.hirsch@unibas.ch

Chris Buck, Bethesda (USA)
buckc@mail.nih.gov

Edward M. Johnson, Norfolk (USA)
johnsoEM@evms.edu

Manola Comar, Trieste (Italy)
comar@burlo.trieste.it

Kamel Khalili, Philadelphia (USA)
kamel.khalili@temple.edu

Mariet Feltkamp, Leiden (The Netherlands)
m.c.w.feltkamp@lumc.nl

Igor Koralknik, Boston (USA)
ikoralni@bidmc.harvard.edu

Pasquale Ferrante, Milan (Italy)
pasquale.ferrante@unimi.it

Walter Royal III, Baltimore (USA)
wroyal@som.umaryland.edu

Jennifer Gordon, Philadelphia (USA)
jennifer.gordon@temple.edu

Hirofumi Sawa, Sapporo (Japan)
h-sawa@czc.hokudai.ac.jp

Scientific Information

Scientific correspondence
Serena Delbue, serena.delbue@unimi.it

Scientific Secretariat

Serena Delbue, Milan (Italy)
serena.delbue@unimi.it

Giulia Ferrante, Copenhagen (Denmark)
giulia.ferrante3@gmail.com

Adam Khalili, Philadelphia (USA)
Adam.Khalili@temple.edu

Organizing Secretariat



Bquadro congressi srl
Via San Giovanni in Borgo, 4 - 27100 PAVIA
tel. +39 0382 302859 - fax +39 0382 27697
bolla@bquadro-congressi.it
www.bquadro-congressi.it

Sponsored by



... il futuro ha il cuore antico

MEDICAL SYSTEMS S.p.A.



Accepted abstracts will be published on Journal of NeuroVirology

5th International Conference

Polyomaviruses and Human Diseases: Basic and Clinical Perspectives

May 9th - 11th, 2013
Grand Hotel Bristol - Stresa, Italy



The polyomaviruses are small DNA viruses that can establish latency in the human host. The name polyomavirus is derived from the Greek roots *poly-*, which means “many,” and *-oma*, which means “tumours.” These viruses were originally isolated in mouse (mPyV) and in monkey (SV40). In 1971, the first human polyomaviruses BK and JC were isolated and subsequently demonstrated to be ubiquitous in the human population. From 2007 and 2012, at least eight other members of the *Polyomaviridae* family have been identified: KI polyomavirus (KIV), WU polyomavirus (WUV), Merkel cell polyomavirus (MCPyV), Human Polyomavirus 6 and 7 (HPyV6, HPyV7), the Trichodysplasia Spinulosa-associated Virus (TSPyV), the Human Polyomavirus 9 (HPyV9), and finally, the MW polyomavirus (MWPyV). While some of them are playing an etiological role in known disorders and malignancies in immunosuppressed patients, no specific human diseases have been associated to the infections of the others. The recent identification of many components of the *Polyomaviridae* family that are able to infect humans represents a strong incentive for the scientific community to improve and increase the research on the potentialities of these viruses. This International Conference, which returns to Italy after ten years from the first edition on the amazing scenery of Lake Maggiore, will provide a unique forum for reporting the most recent discoveries and advances related to both basic scientists and clinicians. The two and a half day conference will cover both major and newly discovered human polyomaviruses, with presentations focused on molecular biology, pathogenesis, genetics and epigenetics, diagnosis and treatment.

THURSDAY, MAY 9TH, 2013

8:30	Registration
9:00	Introduction: Welcome from the scientific committee <i>Pasquale Ferrante, Kamel Khalili</i>
9:15 - 10:45	Session 1: Overview of polyomaviruses Session Chairs: Joe Berger, Pasquale Ferrante Classic polyomaviruses: Basic perspectives <i>Kamel Khalili</i>
9:15 - 9:35	Discovery and characterization of novel polyomaviruses in humans <i>Dave Wang</i>
9:35 - 9:55	Discovery of polyomaviruses in humans and non-human primates <i>Bernhard Ehlers</i>
9:55 - 10:15	Crystal structures and ligand binding studies of the major capsid protein VP1 of Human Polyomavirus 9 and African Green Monkey Polyomavirus-Structural basis of the serological cross-reactivity of the two polyomaviruses <i>Khan Zaigham Mahmo</i>
10:15 - 10:30	Development of a nonhuman primate model of polyomavirus disease in Bolivian squirrel monkeys <i>John A. Vanchiere</i>
10:30 - 10:45	<i>Coffee Break</i>
10:45 - 11:00	Session 2: Clinical features of polyomaviruses associated disease (non-cancer) Session Chairs: Mariet Felkamp, Walter Royal III
11:00 - 12:30	PML in the era of monoclonal antibodies <i>Joseph Berger</i>
11:00 - 11:20	JC virus infection of neurons in the CNS gray matter: the dark side of PML <i>Igor Koralnik</i>
11:20 - 11:40	Old dog-new tricks: molecular mechanisms of BKV pathology in transplantation <i>Hans H. Hirsch</i>
11:40 - 12:00	A case of JC polyomavirus associated nephropathy <i>Irmeli Lautenschlager</i>
12:00 - 12:15	Identification of a novel human polyomavirus in organs of the gastrointestinal tract <i>Sarah Korup</i>
12:15 - 12:30	<i>Buffet Lunch c/o Grand Hotel Bristol</i>
12:30 - 14:30	Special Talk Pathogenesis of human tumor viruses: Lessons from EBV & other viruses <i>Joe Pagano</i> Chair: Kamel Khalili
14:30 - 15:00	Session 3: Clinical and experimental polyomaviruses-associated cancer I Session Chairs: Michele Carbone, Mamhut Safak
15:00 - 16:30	JCV T antigen-induced mechanisms of cellular transformation in humans and animals <i>Jennifer Gordon</i>
15:00 - 15:20	Polyomavirus BK and prostate cancer: a complex interaction of potent clinical relevance <i>Maurizio Provenzano</i>
15:20 - 15:40	Merkel cell polyomavirus genomic sequences in tissues from 10 unselected autopsies <i>Renzo Boldorini</i>
15:40 - 16:00	New evidence supporting the association of Polyomavirus BK DNA sequences with prostate cancer <i>Serena Delbue</i>
16:00 - 16:15	Polycyclic aromatic hydrocarbons - induced ROS accumulation enhances mutagenic potential of human polyomavirus JC <i>Krzysztof Reiss</i>
16:15 - 16:30	<i>Coffee Break</i>
16:30 - 16:50	Session 4: Clinical and experimental polyomaviruses-associated cancer II Session Chairs: Jennifer Gordon, Maurizio Provenzano
16:50 - 17:10	Functional p53 facilitates Simian Virus infection of human cells via IGF-1 <i>Michele Carbone</i>
17:10 - 17:30	Trichodysplasia spinulosa-associated polyomavirus, a bristly bug <i>Mariet Felkamp</i>
17:30 - 17:45	Detection of Human Polyomavirus JCV in Synovial Sarcomas. Further evidence of their neuroectodermal origin <i>Luis Del Valle</i>
17:45 - 18:00	Clinicopathologic characterization of MCPyV-infected Merkel cell carcinomas (MCCs) in a single institution in Italy <i>Alessandro Marando</i>
18:00 - 20:00	Special Session: Short Oral presentations Chair: Serena Delbue, Parmjeet Randhawa

In order of presentation

<i>Antonina Dolei</i>	Up-regulation by JC virus of HERV-W/MSRV/Syncytin-1 human endogenous retroviruses in astrocytes
<i>Anna Bellizzi</i>	Analysis of Polyomavirus JC noncoding control region rearrangements in autoimmune diseases during treatment with natalizumab and anti-TNF agents
<i>Manola Comar</i>	Association of JCV infection with the men infertility
<i>Francesca Isabella De Stefano</i>	JCV large T-Ag in colorectal and gastric carcinogenesis: lack of molecular and immunohistochemical evidence other than PAb416 immunoreactivity
<i>Gabriella Piatti</i>	JCV Reactivation in severely immune-compromised patients
<i>Francesca Sidoti</i>	Cellular response to JCV: a longitudinal study in a population of natalizumab-treated multiple sclerosis patients
<i>Amanda Parker Struckhoff</i>	Association of human neurotropic JC Virus with pediatric gangliosomas and dysembryoplastic neuroepithelial tumors
<i>Elena Anzivino</i>	Possible antiviral effect of ciprofloxacin treatment on BKV replication in a patient with acute renal dysfunction: a case report
<i>Rafael BrandaoVarella</i>	A qualitative semi-nested PCR assay as an alternative to urine cytology for BK Polyomavirus screening after renal transplantation
<i>Michela Cioni</i>	Impact of Polyomavirus BK viremia on long-term allograft outcome in pediatric renal transplant recipients
<i>Julia Manzetti</i>	Influence of Hypoxia on viral replication of different BK Polyomavirus variants
<i>Biswa Sharma</i>	Antiviral effects of Artesunate on Polyomavirus BK replication in primary human renal tubular epithelial cells
<i>Dimitrios Topalis</i>	Mutations in the BKV large T antigen gene confer resistance to cidofovir
<i>Simone Dallari</i>	Longitudinal survey of peripheral blood mononuclear cells subset in MS patients treated with natalizumab
<i>Walter Schaffner</i>	Generation of Simian Virus 40 variants with novel properties
<i>Silvia Bofill-Mas</i>	Potential risk of MCPyV infection through water
<i>Silvia Carluccio</i>	A screening for Merkel Cell Polyomavirus genome in the blood from both immunocompromised and immunocompetent patients
<i>Alessandro Marando</i>	MCPyV infected Merkel cell carcinoma of the stomach
<i>Kazem Siamaque</i>	Global circulation of slowly evolving Trichodysplasia spinulosa-associated Polyomavirus and its adaptation to the human population through alternative T-antigens
<i>Adrian Casillas</i>	Polyomavirus excretion in primary and secondary immune deficiency
<i>Lucia Signorini</i>	Human Polyomaviruses excretion in the urine of kidney transplant patients: a cross-sectional study

FRIDAY, MAY 10TH, 2013

9:30 - 11:10	Session 5: Genetic and epigenetic regulation Session Chairs: Renzo Boldorini, Hans H. Hirsch
9:30 - 9:50	BKV: a neurotropic virus? <i>Ugo Moens</i>
9:50 - 10:10	Are B lymphocytes a reservoir of JC Virus? <i>Raphael Viscidi</i>
10:10 - 10:30	Regulation of JCV DNA replication and recombination by NCCR palindromic secondary structures <i>Ed Johnson</i>
10:30 - 10:50	Cysteine residues in the major capsid protein VP1 of the JCV are important for protein stability and oligomer formation <i>Hirofumi Sawa</i>
10:50 - 11:20	<i>Coffee Break</i>

11:20 - 11:50	Special Talk Novel cell transformation mechanisms for Merkel cell polyomavirus <i>Patrick Moore</i> Chair: Chris Buck
11:50 - 13:00	Session 6: Immune modulation of polyomaviruses and Epidemiology I Session Chairs: Sulie Chang, Ugo Moens
11:50 - 12:10	Molecular regulation of JCV gene expression by immune modulators in glial cells <i>Ilker Sariyer</i>
12:10 - 12:30	Role of the biological drugs on JCV reactivation and PML pathogenesis <i>Valeria Pietropaolo</i>
12:30 - 12:45	Role of BK virus-specific immunity in BKV-related hemorrhagic cystitis after pediatric allogeneic HSCT <i>Giuseppe Quartuccio</i>
12:45 - 13:00	Comparing effects of BK virus agnoprotein and Herpes simplex-1 ICP47 on MHC-I and MHC-II expression <i>Michela Cioni</i>
13:00 - 15:00	<i>Lunch Break (free lunch time)</i>
15:00 - 17:10	Session 7: Epidemiology II Session Chairs: Igor Koralnik, Manuela Nebuloni
15:00 - 15:20	SV40 infection in Fanconi anemia patients <i>Manola Comar</i>
15:20 - 15:40	Is persistent BK viruria without viremia a finding of no clinical significance? <i>Parmjeet Randhawa</i>
15:40 - 15:55	Prevalence of Human Polyomavirus 9, WU and KI in renal transplant and healthy individuals <i>Eszter Csoma</i>
15:55 - 16:10	WU, KI, MW, and MCV Polyomavirus infection in the first two years of life <i>Rebecca Rockett</i>
16:10 - 16:25	Diffuse gastrointestinal bleeding, hemorrhagic cystitis and high-level BK polyomavirus replication in pediatric HSCT patient <i>Minna Koskenvuo</i>
16:25 - 16:40	Subtypes of BKPyV in the urine of stem cell transplant patients with and without hemorrhagic cystitis <i>Marco Ciotti</i>
16:40 - 16:55	In vitro and ex vivo detection of human polyomavirus JC microRNA <i>Simone Gianecchini</i>
16:55 - 17:10	Characterization of T Antigens encoded by TSPyV; evidence for Middle T expression <i>Els van der Meijden</i>
20:00	<i>Gala Dinner "Ristorante Delfino" - Isola Bella</i>

SATURDAY, MAY 11TH, 2013

9:30 - 10:45	Session 8: Biomarkers and potential therapeutic approaches I Session Chairs: Manola Comar, Ed Johnson
9:30 - 9:50	Overview of current therapy in PML <i>Walter Royal III</i>
9:50 - 10:10	Developing vaccines against BKV and JCV <i>Chris Buck</i>
10:10 - 10:25	Commercially available immunoglobulins as a potential therapy for persistent BK viremia <i>Parmjeet Randhawa</i>
10:25 - 10:45	What's going on with the natalizumab treatment for multiple sclerosis patients <i>Pasquale Ferrante</i>
10:45 - 11:15	<i>Coffee Break</i>
11:15 - 12:30	Session 9: Biomarkers and potential therapeutic approaches II Session Chairs: Valeria Pietropaolo, Hirofumi Sawa
11:15 - 11:35	Agnoprotein is a potential biomarker for the early detection of JCV reactivation <i>Ilker Sariyer</i>
11:35 - 11:55	Essential role of Leu/Ile/Phe-rich domain of JCV Agnoprotein in dimer/oligomer formation, protein stability and splicing of viral transcript <i>Mahmut Safak</i>
11:55 - 12:10	Enzyme-linked immunoassay based on recombinant JC Virus-like particles for a JC Polyomavirus serodiagnosis-interlaboratory validation of the method <i>Piotr Kardas</i>
12:10 - 12:25	Host-targeted anti-JCV antiviral therapy to counter development of PML <i>Milton Werner</i>
12:30	Concluding remarks and ECM questionnaire